Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.36 |
| ▸ | APBA1 | Q02410 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.33 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.33 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.33 |
| ▸ | MEN1 | O00255 | 3/20 | 0.31 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.31 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.31 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.31 |
| ▸ | PTP4A3 | O75365 | 1/20 | 0.31 |
| ▸ | PTP4A1 | Q93096 | 1/20 | 0.31 |
| ▸ | PKM | P14618 | 1/20 | 0.30 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.30 |
| ▸ | SNCA | P37840 | 1/20 | 0.30 |
| ▸ | APP | P05067 | 1/20 | 0.30 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
| ▸ | GLA | P06280 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1651451 | 0.86 | CYP3A4 (0.41) | CYP3A4MAPTTSHRCACNA1BAPBA1 | |
| SCHEMBL177943 | 0.78 | CYP3A4 (0.48) | CYP3A4MAPTTSHRCACNA1BAPBA1 | |
| SCHEMBL253005 | 0.77 | — | — | |
| SCHEMBL8409550 | 0.77 | CYP3A4 (0.43) | CYP3A4MAPTTSHRCACNA1BAPBA1 | |
| SCHEMBL7512684 | 0.76 | CYP3A4 (0.46) | CYP3A4MAPTTSHRCACNA1BAPBA1 | |
| SCHEMBL6418608 | 0.76 | TSHR (0.46) | CYP3A4MAPTTSHRCACNA1BAPBA1 | |
| SCHEMBL28141046 | 0.76 | — | — | |
| SCHEMBL17809616 | 0.76 | MAPT (0.41) | CYP3A4MAPTTSHRCACNA1BAPBA1 | |
| SCHEMBL2497210 | 0.76 | CYP3A4 (0.39) | CYP3A4MAPTTSHRCACNA1BAPBA1 | |
| SCHEMBL23630674 | 0.74 | TSHR (0.44) | CYP3A4MAPTTSHRCACNA1BAPBA1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-6548509-B2 | For diagnosis and therapy of treating stress related disorders such as post traumatic stress disorder (PTSD) as well as depression, headache and anxiety | NEUROGEN CORPORATION | 2003-04-15 | — | — | US | disclosed |
| EP-0960110-B8 | 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2002-11-27 | — | — | EP | disclosed |
| US-20020058668-A1 | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | YUAN JUN (US) | 2002-05-16 | — | — | US | disclosed |
| EP-0960110-B1 | 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS | NEUROGEN CORP (US) | 2002-03-20 | — | — | EP | disclosed |
| US-6211187-B1 | POST-TRAUMATIC STRESS; ANTIDEPRESSANTS, ANXIOLYTIC AGENTS | NEUROGEN CORPORATION | 2001-04-03 | — | — | US | disclosed |
| EP-0960110-A1 | 3-ARYL SUBSTITUTED PYRAZOLO 4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF 1?) SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1999-12-01 | — | — | EP | disclosed |
| WO-1998029413-A1 | 3-ARYL SUBSTITUTED PYRAZOLO[4,3-d]PYRIMIDINE DERIVATIVES; CORTICOTROPIN-RELEASING FACTOR RECEPTOR (CRF1) SPECIFIC LIGANDS | NEUROGEN CORPORATION (US) | 1998-07-09 | — | — | WO | disclosed |
| US-5723608-A | 3-aryl substituted pyrazolo 4,3-d!pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | NEUROGEN CORPORATION (US) | 1998-03-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020058668-A1 | 3-aryl substituted pyrazolo[4,3-D]pyrimidine derivatives; corticotropin-releasing factor receptor (CRF1) specific ligands | CRH, CRHR1, CRHR2 | CYP3A4 1148/4885MAPT 3345/4885TSHR 139/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.